Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | SDHA | P31040 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CALML3 | P27482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478797 | 0.84 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2452755 | 0.77 | MAOA (0.40) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6335892 | 0.75 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6209789 | 0.75 | F10 (0.32) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2480117 | 0.74 | MEN1 (0.41) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6480076 | 0.71 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1843557 | 0.70 | MAOA (0.35) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5219360 | 0.70 | MAOA (0.38) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7818376 | 0.70 | MAOA (0.44) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5325706 | 0.70 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | MAOA 743/4885MAOB 739/4885PTGS1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.